System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Studies

Interventional Active not recruiting

NCT06398951 on ClinicalTrials.gov

HFNC vs Two Nare HFNC in Extubated Patients

Official title: A Comparison of Conventional High Flow Nasal Cannula vs Two-nare Size High Flow Nasal Cannula: A Randomized Crossover Trial in Extubated Patients

  • Sponsor: Peninsula Health
  • Enrollment: 50 (Actual)
  • Study start: 2023-07-01 (Actual)
  • Primary completion: 2025-09-01 (Estimated)
  • Study completion: 2025-09-01 (Estimated)
  • Allocation: Randomized
  • InterventionModel: Crossover
  • Masking: None
  • PrimaryPurpose: Treatment

Brief Summary

High flow nasal cannula (HFNC) are introduced to clinical practice to improve oxygenation. Our group were the first to report the use of HFNC in extubated patients that showed comparable delivery of oxygen and improved comfort. These HFNC are subsequently shown to be useful in several clinical conditions in critically ill patients including respiratory failure due to hypoxia, hypercapnia (exacerbation of chronic obstructive lung disease), or post-extubation, pre-intubation oxygenation, and others.

Recently a new mode of high flow oxygen therapy has been presented on the market where the prongs of high flow have two different diameters. These two-nare size high flow nasal cannula are capable of delivering gases at a flow rate of 15-50 L/min, similar to the conventional HFNP but the difference in the diameters provide different levels of positive pressure as compared to conventional HFNP. This positive pressure could help in gas exchange of patients who need more oxygen. These devices are approved by the Therapeutic Goods Administration (TGA); the medicine and therapeutic regulatory agency of the Australian Government.

Our aim is to compare the two size nare high flow nasal cannula with conventional high flow nasal cannula in extubated patients in intensive care unit in a randomised crossover trial. The comparison will include arterial blood gasses, physiological data including heart rate, respiratory rate, saturations as well as comfort and tolerance of the patients to two size nare high flow nasal cannuale.

Conditions

  • Oxygen Deficiency

Intervention / Treatment

  • Device: Two nare high flow nasal cannula

Primary Outcome Measures

  • Blood gasses (PaO2 in mmHg) (30 minutes each for a total of one hour.)
    To compare if there is difference in PaO2 between two nare and connventional high flow nasal cannula.
  • Blood gasses (PaCO2 in mmHg) (30 minutes each for a total of one hour.)
    To compare if there is difference in PaCO2 between two nare and connventional high flow nasal cannula.
  • Blood gasses (SaO2 percentage) (30 minutes each for a total of one hour.)
    To compare if there is difference in SaO2 between two nare and connventional high flow nasal cannula.

Countries

Australia

Locations and Investigators

  • Frankston Hospital, Frankston, Australia

Study Officials

  • RAVINDRANATH TIRUVOIPATI, PhD (Principal Investigator) — Peninsula Health